缅北禁地

Skip to main content

Staff Profile

Dr Santu Saha

Research Associate

  • Email: santu.saha@ncl.ac.uk
  • Address: Leukaemia Research Cytogenetics Group
    Translational and Clinical Research Institute
    缅北禁地
    Level 6, Herschel Building
    Brewery Lane
    缅北禁地-Upon-Tyne, UK
    NE1 7RU


Background

Current position:


2022 – till now: Research Associate at Leukaemia Research Cytogenetics Group (LRCG) and working on the project entitled ‘Novel drug treatments through repurposing of FDA-approved drugs for improved treatment of high-risk acute lymphoblastic leukaemia’ funded by the Little Princess Trust.

Mentor: Christine Harrison

 

Qualifications:


2014:                     Ph.D., University of Kalyani, India

2009:                     M.Sc., University of Kalyani, India

2007:                     B.Sc. Bangalore University (Garden City College), India

 

Previous appointments:


2019 – 2022:       Newton International Fellow (Academy of Medical Sciences), 缅北禁地, UK

2017 - 2018:        Bio-bank Technologist, Tata Medical Center, India

2015 –2017:        Research Associate, Chittaranjan National Cancer Institute, India

2014:                     Research Associate, Institute of Life Sciences, India

2010 – 2014:       Research Fellow, University of Kalyani, India

 

Awards:


2022:                     Wellcome Trust Translational Partnership (WTTP)  Translational Explorer award

2022:                     Justice, Equity, Diversity and Inclusion (JEDI) award of Life Science Editors Foundation

2021:                     Wellcome Trust Translational Partnership (WTTP) Early Translational Research award

2020:                     Invited speaker (Young Investigator) European SocieTy for Radiotherapy and Oncology (ESTRO)

2019:                     ESTRO Mobility Grant award

2019:                     H2020 Marie Sklodowska-Curie Actions Seal of Excellence award

2019:                     Newton International Fellowship of Academy of Medical Sciences

2017:                   The Union for International Cancer Control (UICC) Technical Fellowship

2015:                   Research Associateship of Department of Biotechnology (DBT), India

2009:                   Qualified Graduate Aptitude Test (GATE) conducted by Indian Institute of

Technology (IIT)

Research

Research Funding:

2022:                Establishing the drug-gene association matrix pipeline of childhood leukaemia. Santu Saha (lead applicant), Christine Harrison (co-applicant/mentor), Wellcome Trust Translational Partnership (WTTP) £5,580.00

2021:              Establish 3D-spheroid co-culture model to investigating the immunomodulatory impact of PARP inhibitor (PARPi) and radiotherapy combination in Head and neck cancer. Santu Saha (lead applicant), Nicola Curtin (co-applicant), Wellcome Trust Translational Partnership (WTTP) £10,000.00

2019:             Investigating therapeutic application of PARP inhibitor as chemo-radiosensitser in cervical cancer and its effect on renal protection. Santu Saha (lead applicant), Nicola Curtin (co-applicant/mentor)- Academy of Medical Sciences £99,000.00

2019:            The effect of PARPi on therapy resistance of cervical cancer stem cells”. Santu Saha (lead applicant) and Anna Dubrovska (co-applicant) - ESTRO of €2,300.00 (travel grant).

2019:             Research England Global Challenges Research Fund (GCRF) Quality Related (QR) research support through the 缅北禁地 Faculty of Medical Sciences ‘strategic initiative’ parts to support the Newton International project as the project matches the merit of Official Development Assistance (ODA). Santu Saha (lead applicant) and Nicola Curtin (co-applicant/mentor), £20,000.00 (consumable).

2017:          Investigating radiosensitisation in cervical cancer using DNA damage response pathway inhibitors. Santu Saha (lead applicant) and Nicola Curtin (co-applicant) - UICC of $3,400.00 (travel grant).

2015:                   Analysis of Hyaluronan-CD44 mediated signaling in head and neck squamous cell carcinoma. Santu Saha (lead applicant) and Chinmay Panda (co-applicant/mentor) – Department of Biotechnology (DBT), India of ₹12,54400.00

Teaching

2020:     Mentored Ms. Hannah Mearns an UG student at 缅北禁地 University to complete her dissertation

2018:     Mentored Ms. Arpita Maity, at Tata Medical Center, Kolkata, India on clinical sample bio-banking

2016:     Mentored Mr. Gourab Mallick, Bengal School of Technology, India for his MPharm dissertation

2016:     Mentored Mr. Arindam Sain, of University of Calcutta, India, for his MSc dissertation

2015:     Mentored Mr. Subhrangsu Chakraborty, of GITAM University, India for his MSc dissertation
Publications

  • Articles

    • Saha S, Howarth R, Sharma-Saha S, Kelly C. . Biology Open 2023, 12(5), bio059949.
    • Saha S, Rundle S, Kotsopoulos IC, Begbie J, Howarth R, Pappworth IY, Mukhopadhyay A, Kucukmetin A, Marchbank KJ, Curtin N. . Cancers 2022, 14(17), 4288.
    • Sudhindar PD, Wainwright D, Saha S, Howarth R, McCain M, Bury Y, Saha SS, McPherson S, Reeves H, Patel AH, Faulkner GJ, Lunec J, Shukla R. . Cancers 2021, 13(20), 5079.
    • Patra A, Saha SK, Sen TK, Carrella L, Musie GT, Khuda-Buksha AR, Bera M. . European Journal of Inorganic Chemistry 2014, 2014(30), 5217-5232.
    • Saha SK, Khuda-Bukhsh AR. . European Journal of Pharmacology 2014, 744, 132-146.
    • Samadder A, Das J, Das S, De A, Saha SK, Bhattacharyya SS, Khuda-Bukhsh AR. Poly (lactic-co-glycolic) acid loaded nano-insulin has greater potentials of combating arsenic induced hyperglycemia in mice: some novel findings. Toxicology and applied pharmacology 2013, 267(1), 57-73.
    • Saha SK, Sikdar S, Mukherjee A, Bhadra K, Boujedaini N, Khuda-Bukhsh AR. Ethanolic extract of the Goldenseal, Hydrastis canadensis, has demonstrable chemopreventive effects on HeLa cells in vitro: Drug–DNA interaction with calf thymus DNA as target. Environmental Toxicology and Pharmacology 2013, 36(1), 202-214.

  • Book Chapters

    • KhudaBukhsh AR, Saha SK, Das S, Saha SS. . In: Cancer (Second Edition). Academic Press, 2021, pp.191-202.
    • Khuda-Bukhsh AR, Samadder A, Saha SK. . In: Cancer Stem Cells: New Horizons in Cancer Therapies. Berlin: Springer, 2020, pp.1-13.
    • Khuda-Bukhsh AR, Das S, Saha SK. . In: Preedy V, ed. Cancer : Oxidative Stress and Dietary Antioxidants. Amsterdam: Elsevier Science, 2014, pp.77-89.

  • Conference Proceedings (inc. Abstracts)

    • Shahid Iqbal M, Jamil F, Kovarik J, Cunnell M, Kelly C, Saha S, Patil R, O'Hara J, Hamilton D, Fox H, Warner L, Ahmed O, Waton A, Saleh D. . In: ICHNO–ECHNO 2022 Congress. 2022, Brussels and Virtual: European SocieTy for Radiotherapy and Oncology.
    • Saha S, Howarth R, Pappworth I, Marchbank K, Curtin N. . In: 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2020, Virtual: Elsevier Ltd.
    • Saha S, Howarth R, Dubrovska A, Marchbank K, Curtin N. . In: ESTRO 2020 Online Congress. 2020, Online: Elsevier.
    • Saha S, Howarth R, Pappworth I, Gentles L, Marchbank K, Curtin N. . In: DNA Damage Responses and Cancer: Innovations from Radiobiology to Radiotherapy conference. 2020, Virtual: European Association for Cancer Research.
    • Saha S, Mukhopadhyay D, Chakraborty B, Alam N, Biswas J, Roy A, Roychoudhury S, Panda CK. . In: Recent Trends in Microbiology Conference. 2017, Kolkata, India.

  • Digital or Visual Media

    • Saha S. . Biology Open 2023, 12(5), bio059987.

  • Editorial

    • Saha S. . SelectScience 2021.

  • Reviews

    • Saha SK, Maiti G, Roychoudhury S, Panda CK. . The Nucleus 2017, 60(2), 111-119.
    • Khuda-Bukhsh AR, Das S, Saha SK. . Nutrition and Cancer 2014, 66(2), 194-205.
    • Saha SK, Khuda-Bukhsh AR. Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: current trends. European Journal of Pharmacology 2013, 714(1-3), 239-248.